← Back to Screener
CytomX Therapeutics, Inc. (CTMX)
Price$4.89
Favorite Metrics
Price vs S&P 500 (26W)31.33%
Price vs S&P 500 (4W)-2.19%
Market Capitalization$1.06B
P/E Ratio (Annual)23.50x
All Metrics
Book Value / Share (Quarterly)$0.58
P/TBV (Annual)7.32x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)12.72%
Cash Flow / Share (Quarterly)$-0.45
Price vs S&P 500 (YTD)4.40%
Net Profit Margin (TTM)-22.79%
EPS (TTM)$0.03
10-Day Avg Trading Volume5.14M
EPS Excl Extra (TTM)$0.03
Revenue Growth (5Y)-5.37%
EPS (Annual)$-0.13
ROI (Annual)-17.54%
Net Profit Margin (5Y Avg)-99.53%
Cash / Share (Quarterly)$0.81
P/E Basic Excl Extra (TTM)26.73x
Revenue Growth QoQ (YoY)-98.26%
P/E Normalized (Annual)23.50x
ROA (Last FY)-11.46%
Revenue Growth TTM (YoY)-44.82%
EBITD / Share (TTM)$-0.15
ROE (5Y Avg)-81.98%
Operating Margin (TTM)-29.35%
Cash Flow / Share (Annual)$-0.45
P/B Ratio10.68x
P/B Ratio (Quarterly)7.29x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)13.71x
Net Interest Coverage (TTM)-87.50x
ROA (TTM)-11.91%
EV / EBITDA (TTM)42.82x
EPS Incl Extra (Annual)$-0.13
Current Ratio (Annual)3.09x
Quick Ratio (Quarterly)2.98x
3-Month Avg Trading Volume5.59M
52-Week Price Return652.35%
P/E Incl Extra (TTM)26.73x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.58
P/S Ratio (Annual)13.87x
Asset Turnover (Annual)0.50x
52-Week High$8.21
Operating Margin (5Y Avg)-103.81%
EPS Excl Extra (Annual)$-0.13
CapEx CAGR (5Y)-37.46%
Tangible BV CAGR (5Y)5.15%
26-Week Price Return35.31%
Quick Ratio (Annual)2.98x
13-Week Price Return5.07%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.09x
Enterprise Value$1,044.44
Revenue / Share Growth (5Y)-23.99%
Asset Turnover (TTM)0.52x
Book Value / Share Growth (5Y)-23.01%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-22.48%
Cash / Share (Annual)$0.81
3-Month Return Std Dev133.76%
Net Income / Employee (TTM)$-0
ROE (Last FY)-17.54%
Net Interest Coverage (Annual)-47.58x
EPS Basic Excl Extra (Annual)$-0.13
P/FCF (TTM)113.67x
Receivables Turnover (TTM)29.79x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.03
Receivables Turnover (Annual)29.79x
ROI (TTM)-19.77%
P/S Ratio (TTM)13.87x
Pretax Margin (5Y Avg)-98.67%
Revenue / Share (Annual)$0.55
Tangible BV / Share (Annual)$0.58
Price vs S&P 500 (52W)622.52%
P/E Ratio (TTM)26.73x
EPS Growth TTM (YoY)-93.03%
Year-to-Date Return7.04%
5-Day Price Return7.55%
EPS Normalized (Annual)$-0.13
ROA (5Y Avg)-11.50%
Net Profit Margin (Annual)-22.79%
Month-to-Date Return-2.98%
Cash Flow / Share (TTM)$-0.39
EBITD / Share (Annual)$-0.15
Operating Margin (Annual)-29.35%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-81.98%
P/E Excl Extra (TTM)26.73x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.03
P/TBV (Quarterly)7.32x
P/B Ratio (Annual)7.29x
Pretax Margin (TTM)-22.48%
Book Value / Share (Annual)$0.58
Price vs S&P 500 (13W)4.38%
Beta2.36x
P/FCF (Annual)352.37x
Revenue / Share (TTM)$0.45
ROE (TTM)-19.77%
52-Week Low$0.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.27
4.27
4.33
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CTMXCytomX Therapeutics, Inc. | 13.87x | -44.82% | — | — | $4.89 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
CytomX Therapeutics is a clinical-stage oncology company developing probody therapeutics—masked, conditionally activated biologics designed to target the tumor microenvironment. The company's proprietary technology platform creates cancer immunotherapies that activate specifically in tumors while remaining inactive in healthy tissues, enhancing efficacy and reducing potential side effects.